473417-48-0

Basic information

• Product Name: 5-bromo-2-fluoro-4-methoxybenzaldehyde
• Synonyms: 5-bromo-2-fluoro-4-methoxybenzaldehyde
• CAS NO: 473417-48-0
• Molecular Formula: C₈H₆BrFO₂
• Molecular Weight: 233.0344432
• Mol File: 473417-48-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-bromo-2-fluoro-4-methoxybenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-fluoro-4-methoxybenzaldehyde(473417-48-0)
• EPA Substance Registry System: 5-bromo-2-fluoro-4-methoxybenzaldehyde(473417-48-0)

Safety Data

• Hazardous Substances Data: 473417-48-0(Hazardous Substances Data)

Upstream product

• 331-64-6 2-fluoro-4-methoxy-benzaldehyde 
• 4885-02-3 Dichloromethyl methyl ether 
• 450-88-4 1-bromo-4-fluoro-2-methoxybenzene 
• 147460-41-1 2-bromo-5-fluorophenol 
• 2369-34-8 2,5-dibromo-5-fluorophenol 
• 861928-16-7 2,4-dibromo-5-fluoroanisole 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 914397-21-0 5-bromo-2-fluoro-4-hydroxybenzaldehyde 
• 914397-16-3 5-bromo-2-fluoro-4-methoxybenzaldehyde dimethylacetal 
• 914397-12-9 6-bromo-7-methoxyquinazolin-2-amine 
• 1427405-27-3 methyl 6-methoxy-1H-indazole-5-carboxylate 
• 1191932-43-0 2-amino-8-bromo-7-methoxy-6-[2-methyl-5-N-(2-piperidino-5-trifluoromethylphenyl)carbamoylphenyl]quinazoline 
• 1191932-28-1 2-amino-8-bromo-6-(5-N-{2-[N-(3-dimethylaminopropyl)-N-methylamino]-5-trifluoromethylphenyl}carbamoyl-2-methylphenyl)-7-methoxyquinazoline 
• 1191929-34-6 2-amino-7-hydroxy-6-[2-methyl-5-(3-trifluoromethylbenzamide)phenyl]-8-(2-pyridyl)quinazoline 
• 1191929-31-3 2-amino-7-methoxy-6-[2-methyl-5-(3-trifluoromethylbenzamide)phenyl]-8-phenylquinazoline 
• 1191929-32-4 2-amino-7-methoxy-6-[2-methyl-5-(3-trifluoromethylbenzamide)phenyl]-8-(2-pyridyl)quinazoline 
• 1191932-55-4 2-amino-8-bromo-7-methoxy-6-[2-methyl-5-N-(4-trifluoromethylpyridin-2-yl)carbamoylphenyl]quinazoline 
• 1191932-18-9 2-amino-8-bromo-7-methoxy-6-[2-methyl-5-((3-trifluoromethyl)benzamido)phenyl]quinazoline 
• 1191932-17-8 2-amino-7-methoxy-6-[2-methyl-5-((3-trifluoromethyl)benzamido)phenyl]quinazoline 
• 1191932-26-9 3-(2-Amino-8-bromo-7-methoxyquinazolin-6-yl)-4-methyl benzoic acid 
• 1191932-25-8 3-(2-Amino-7-methoxyquinazolin-6-yl)-4-methyl benzoic acid 

Relevant articles and documents

ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-1" PATHWAY AND METHODS OF USE THEREOF

The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.

ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-I' PATHWAY AND METHODS OF USE THEREOF

The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.

ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-I" PATHWAY AND METHODS OF USE THEREOF

The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.

STING AGONIST COMPOUNDS

Compounds of general formula (I), of general formula (II), of general formula (III), of general formula (IV), of general formula (V), of general formula (VI), and their pharmaceutically acceptable salts, wherein all variables are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.

BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS

Compounds of general formula (Ia), compounds of general formula (Ia′), compounds of general formula (Ib), compounds of general formula (Ib′), compounds of general formula (I), compounds of general formula (I′), and their pharmaceutically acceptable salts,

PHTHALAZINE DERIVATIVES AS INHIBITORS OF PARP1, PARP2 AND/OR TUBULIN USEFUL FOR THE TREATMENT OF CANCER

The application relates to phthalazine derivatives of formula (I) which are inhibitors of PARP1, PARP2 and/or tubulin and thus useful for the treatment of cancer. Also disclosed are pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.

2-AMINOQUINAZOLINE DERIVATIVE

A 2-aminoquinazoline derivative represented by formula (I) {wherein R1 represents a hydrogen atom, or the like, R2 represents a hydrogen atom, R3 represents formula (II) [wherein A1 represents formula (III), or the like, R8 represents lower alkyl, or the like, and R9 represents optionally substituted aryl, or the like], R4 represents hydroxy, or the like, and R5 represents optionally substituted aryl, or the like}, or a pharmaceutically acceptable salt thereof is provided.

TETRACYCLIC COMPOUND

Provided are a tetracyclic compound represented by the formula (I): [in the formula(I),the formula (A) represents a benzene ring or the like, X represents CH or a nitrogen atom, Q represents -O- or the like, R1, R2, and R3 may be the same or different and each represent a hydrogen atom or the like, 1, m, and n each represent an integer from one to the maximum substitutable number of substituents, and R4 and R5 may be the same or different and each represent a hydrogen atom or the like], or a pharmaceutically acceptable salt thereof, and the like.

2-AMINOQUINAZOLINE DERIVATIVES

2-Aminoquinazoline derivatives represented by the general formula (I) or pharmacologically acceptable salts thereof: (I) wherein R1 and R2 are each independently hydrogen, substituted or unsubstituted lower alkyl, or the like; X is a bond or CR7aR7b (wherein R7a and R7b are each independently hydrogen or the like); when X is a bond, R3 is substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group, while when X is CR7aR7b, R3 is substituted or unsubstituted lower alkoxy, substituted or unsubstituted aryl, or the like; R4 is hydrogen, hydroxy, substituted or unsubstituted lower alkoxy, or the like; and R5 is hydrogen, substituted or unsubstituted aryl, or the like.

PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME

The present invention provides a novel compound having an excellent JNK inhibitory effect. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein R1 designates -(CO)h-(NRa)j-(CRb=CRc)k-Ar (wherein Ra, Rb and Rc each independently designate a hydrogen atom, a halogen atom, hydroxyl group, an optionally substituted C1-6 alkyl group or the like; Cy designates a 5- or 6-membered heteroaryl; and V each independently designate the formula -L-X-Y (wherein L designates a single bond, an optionally substituted C1-6 alkylene group or the like; X designates a single bond or the formula -A- (wherein A designates NR2, O, CO, S, SO or SO2) and so on; and Y designates a hydrogen atom, a halogen atom, nitro group or the like).